Pharming « Terug naar discussie overzicht

Pharming in november dan toch scoren

3.056 Posts, Pagina: « 1 2 3 4 5 6 ... 107 108 109 110 111 112 113 114 115 116 117 ... 149 150 151 152 153 » | Laatste

Omlaag ↓

[verwijderd] 22 november 2016 09:19

spelletje gaat beginnen?...

[verwijderd] 22 november 2016 09:22

quote:
jurpsy schreef op 22 november 2016 09:10:
[...]

Men heeft de inkomsten van de claimemissie absoluut niet nodig om de deal te sluiten.
Het afronden van de deal wordt verwacht rond 6/12.

"De aankooptransactie zal worden afgerond zodra.....dit wordt verwacht vóórdat de claimemissie is afgerond."

Uit het koeterwaals maak ik op dat de deal met Valeant afgerond wordt voor de afronding van de claim-emissie en dat is dus voor 6 december.
Verder zullen die paar dagen verschil me overigens een biet wezen.

jurpsy 22 november 2016 09:25

quote:
Beur schreef op 22 november 2016 09:22:
[...]"De aankooptransactie zal worden afgerond.....vóórdat de claimemissie is afgerond."

Uit het koeterwaals maak ik op dat de deal met Valeant afgerond wordt voor de afronding van de claim-emissie en dat is dus voor 6 december.
Verder zullen die paar dagen verschil me overigens een biet wezen.

zo is dat ;

Pharming intends to use the net proceeds from the issue of all of the New Shares
(expected to be €11.3 million), together with the net proceeds from the placement
of the Convertible Bonds (expected to be approximately €53.9 million after costs of
€8.1 million) and the net proceeds of the New Debt Facility (expected to be
approximately €35.9 million after costs of €0.57 million and a retention for liquidity
of €1.26 million), in total approximately €101 million, primarily for:
• The payment of US$60 million (or €56.7 million) to Valeant as an upfront
payment in respect of the acquisition by Pharming of all North American
commercialisation rights to RUCONEST® (the Upfront Amount);
• Repayment of the existing loan held with Oxford Finance LLC and Silicon Valley
Bank, which will cost approximately €16.2 million (or $17.2 million);
• Costs relating to the Transaction of approximately €0.7 million in total;
• Financing the acceleration of sales efforts in respect of RUCONEST® in the USA
including core marketing activities up to an amount of €20.0 million;
• Financing the acceleration of sales efforts in respect of RUCONEST® in the EU
including a modest expansion of commercial activity in the EU up to an amount
of €7.0 million, following the addition of a further 21 countries to Pharming’s
direct commercialisation territories after amendment of the Company’s
distribution agreement with SOBI, and the introduction of self-administration
home kits if the European Commission adopts the positive opinion issued on 11
November 2016 by the Committee for Medicinal Products for Human Use and
approves the use of such kits for RUCONEST®, including financing the
acceleration of clinical investigation of new routes of administration for
RUCONEST®, including specifically intramuscular and sub-cutaneous
formulations; and
• Any balance (expected to be approximately €0.5 million) will be used for general
corporate purposes as appropriate.
Closing of the New Debt Facility is conditional on a minimum raise of approximately
€40 million (gross) between the Offer and the Convertible Bonds. The Management
Board believes that based on the demand for Convertible Bonds it will be able both
to trigger completion of the New Debt Facility and to close the Transaction.
Consequently, there is no minimum amount required to be raised from the Rights
Offer.
Closing of the Transaction is expected shortly before 6 December 2016, and will be
executed as soon as the Company has secured sufficient funds to do so. This may be
before the closing of the Exercise Period, if the documentation for the Convertible
Bonds can be completed before then. Apart from the condition that Pharming
obtains sufficient financing for payment of the Upfront Amount, closing of the
Transaction is subject to the following customary conditions (which may be waived
by Pharming or Valeant to the extent legally permissible): no law or court order
making the Transaction illegal or otherwise prohibiting the closing of the Transaction;
execution or termination of certain agreements among Pharming and Valeant and
the delivery of certain documents by Valeant to Pharming; no material adverse
change regarding the assets or product subject to the Transaction; no breach by
either party of representations and warranties or covenants provided for in the
agreement with Valeant (subject to customary materiality qualifiers).
In the event that the gross proceeds from the Convertible Bonds and the Offer
together are less than €40 million and as a result the Transaction cannot close, the
Debt Components and the Rump Offer will not be closed as well. It will not be
possible, however, to reverse the closing of the Rights Offer and return the proceeds
to the investors who have paid for the New Shares. In that case only, the net
proceeds of the Rights Offer will be used for general corporate purposes and to
extend the cash runway of the Company to 2019, including expenditure on the
acceleration of sales of RUCONEST® in Europe and other territories and development
of other new routes of administration for RUCONEST® such as intramuscular delivery
and subcutaneous delivery, in addition to the roll-out of self-administration home
kits for RUCONEST® in Europe.

En nu de boer op met je bieten..

suc6,

jurps

[verwijderd] 22 november 2016 09:32

Kan iemand eff kort uitleggen hoe het werkt
Ik heb nu 1900 aandelen in mijn bezit
wat gaat er gebeuren vanaf morgen
en wat is slim te doen

DeZwarteRidder 22 november 2016 09:33

• Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

Kun je nagaan wat de promotie in de USA gaat kosten.

Ik heb het al vele malen gezegd: Zodra De Vries geld ter beschikking heeft, vliegt het de deur weer uit.

Volgend jaar weer een emissie....??? lol

jurpsy 22 november 2016 09:36

quote:
DeZwarteRidder schreef op 22 november 2016 09:33:
• Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

Kun je nagaan wat de promotie in de USA gaat kosten.

Ik heb het al vele malen gezegd: Zodra De Vries geld ter beschikking heeft, vliegt het de deur weer uit.

Volgend jaar weer een emissie....??? lol

.....je bent een ondernemer 'pur sang" ?

Happynewyear 22 november 2016 09:37

Kosten voor de..... uit?

[verwijderd] 22 november 2016 09:39

quote:
DeZwarteRidder schreef op 22 november 2016 09:33:
• Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest expansion of commercial activity in the EU up to an amount of €7.0 million,

Kun je nagaan wat de promotie in de USA gaat kosten.

Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;

DeZwarteRidder 22 november 2016 09:40

quote:
Happynewyear schreef op 22 november 2016 09:37:
Kosten voor de..... uit?

Natuurlijk, zo gaat dat al ca 20 jaar bij Pharming.

DeZwarteRidder 22 november 2016 09:43

quote:
Beur schreef op 22 november 2016 09:39:
[...] Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;

Dus in totaal gaan er binnenkort 27 miljoen de deur uit ALLEEN VOOR PROMOTIE EN MARKETING.

Wie zei er ook weer dat Pharming binnenkort winst gaat maken....????

[verwijderd] 22 november 2016 09:45

quote:
DeZwarteRidder schreef op 22 november 2016 09:43:
[...]

Dus in totaal gaan er binnenkort 27 miljoen de deur uit ALLEEN VOOR PROMOTIE EN MARKETING.

Wie zei er ook weer dat Pharming binnenkort winst gaat maken....????

promotie en marketing heb je nodig om een goeie sales (en dus inkomsten) te bewerkstelligen...

als je dat niet begrijpt...tsja...

[verwijderd] 22 november 2016 09:45

quote:
Beur schreef op 22 november 2016 09:39:
[...] Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including core marketing activities up to an amount of €20.0 million;

Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.

DeZwarteRidder 22 november 2016 09:47

quote:
moneymaker_BX schreef op 22 november 2016 09:32:
Kan iemand eff kort uitleggen hoe het werkt
Ik heb nu 1900 aandelen in mijn bezit
wat gaat er gebeuren vanaf morgen
en wat is slim te doen

1) je kunt de claims verkopen als een soort 'dividend'.
2) je kunt met de claims aandelen bijkopen.

Wat is slim?

Kop is verkopen en munt is bijkopen (of andersom).

jurpsy 22 november 2016 09:47

quote:
AJ2016 schreef op 22 november 2016 09:45:
[...]

Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.

In November 2016, one of the Group’s principal competitors, Shire, announced to its patients and physicians
that it is unable to supply its plasma-derived C1 inhibitor product Cinryze® for prophylaxis of HAE, because of
a production issue at its supplier Sanquin in the Netherlands. This shortage of supply is expected by Shire to
be rectified by early 2017. At the current time, RUCONEST® is the only alternate product with published data
showing good efficacy in prophylaxis although it has not yet obtained approval for the indication in the USA,
and it may be that some physicians feel it is a suitable alternative for patients unable to obtain their supply of
Cinryze®. It is too early to say whether this will improve sales of RUCONEST® but this may be the outcome of
this situation, in which case the financial and trading position of the Group would be improved.

[verwijderd] 22 november 2016 09:49

quote:
AJ2016 schreef op 22 november 2016 09:45:
[...]

Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.

Laten we hopen dat men een bijzinnetje omtrent eventueel "slechts flankerend benodigd onderzoek" waarover De Vries repte, gewoon vergeten is ;)

[verwijderd] 22 november 2016 09:50

[i]"Closing of the New Debt Facility is conditional on a minimum raise of approximately €40 million (gross) between the Offer and the Convertible Bonds. The Management Board believes that based on the demand for Convertible Bonds it will be able both to trigger completion of the New Debt Facility and to close the Transaction. Consequently, there is no minimum amount required to be raised from the Rights Offer.
Closing of the Transaction is expected shortly before 6 December 2016, and will be executed as soon as the Company has secured sufficient funds to do so." [/i]

$rob$ 22 november 2016 09:51

quote:
Happynewyear schreef op 22 november 2016 09:37:
Kosten voor de..... uit?

Ja, en dat al 18 jaar.......

[verwijderd] 22 november 2016 09:53

quote:
jurpsy schreef op 22 november 2016 09:47:
[...]

In November 2016, one of the Group’s principal competitors, Shire, announced to its patients and physicians
that it is unable to supply its plasma-derived C1 inhibitor product Cinryze® for prophylaxis of HAE, because of
a production issue at its supplier Sanquin in the Netherlands. This shortage of supply is expected by Shire to
be rectified by early 2017. At the current time, RUCONEST® is the only alternate product with published data
showing good efficacy in prophylaxis although it has not yet obtained approval for the indication in the USA,
and it may be that some physicians feel it is a suitable alternative for patients unable to obtain their supply of
Cinryze®. It is too early to say whether this will improve sales of RUCONEST® but this may be the outcome of
this situation, in which case the financial and trading position of the Group would be improved.

Goed punt, maar dat is wat anders dan goedkeuring en zodra Cinryze weer beschikbaar is ebt eventuele omzet voor Ruconest op prophylaxis wel weer weg. Maar alle beetjes helpen, dat is zo. Anderzijds: de kosten van een volledige fase III zullen ongetwijfeld ook zeer omvangrijk zijn.

DeZwarteRidder 22 november 2016 09:55

quote:
AJ2016 schreef op 22 november 2016 09:45:
[...]Yep, en voor diegenen die dachten dat er op korte termijn iets te verwachten valt van prophylaxis de volgende quote uit de prospectus: "After having agreed the parameters for the ongoing clinical development of RUCONEST® in prophylaxis of HAE with the FDA, the Company expects that any further clinical development in this study program (Study 3201) will be completed by the end of 2018 at the latest, enabling a new application for a BLA with the FDA in prophylaxis to be filed soon after such studies are complete, assuming that the necessary endpoints are achieved." Dus geen enkele verwijzing naar een accelerated approval.

Tegen die tijd zijn er waarschijnlijk al 2 of 3 concurrenten op de markt en is Pharming weer te laat.

jurpsy 22 november 2016 09:55

Financing the acceleration of sales efforts in respect of RUCONEST® in the USA including the following core marketing activities up to an amount of €20.0 million including the following activity:

o strengthening of medical science liaison activities, and the addition of extra sales representatives to
complement the existing team who have very large areas to cover at present;
o unconditional support for the HAEA, the HAE patients’ association in the USA, and for the
University of California San Diego’s HAE Center of Excellence and other centres of excellence. This
is necessary to enable proper support of HAE patients with difficulties in insurance, treatment or
disease state, and must be unconditional to comply with all relevant legislation for both the
Company and the various recipients including the Sunshine Act; and
o additional activities to involve Key Opinion Leaders in HAE with RUCONEST® and its relative merits
and benefits for patients, including help with development of new dosage forms. As with assistance
for the patients’ association and related bodies, these activities are carefully planned to conform
with the spirit and the word of all relevant legislation including the Sunshine Act, and may include
non-product-specific speaking opportunities, advisory positions and product-neutral research,
none of which may offer an inducement to a physician to prescribe or a patient to choose any
Pharming product.
• Financing the acceleration of sales efforts in respect of RUCONEST® in the EU including a modest
expansion of commercial activity in the EU up to an amount of €7.0 million, following the addition of a
further 21 countries to Pharming’s direct commercialisation territories after amendment of the
Company’s distribution agreement with SOBI, and the introduction of self-administration home kits if the
European Commission adopts the positive opinion issued on 11 November 2016 by the Committee for
Medicinal Products for Human Use (CHMP) and approves the use of such kits for RUCONEST®, including
financing the acceleration of clinical investigation of new routes of administration for RUCONEST®,
including specifically intramuscular and sub-cutaneous formulations; and
• Any balance (expected to be approximately €0.5 million) will be used for general corporate purposes as
appropriate.
Pharming intends to use its existing cash resources and cash derived from operations to service its existing
research and development costs and the costs of the Debt Components.

3.056 Posts, Pagina: « 1 2 3 4 5 6 ... 107 108 109 110 111 112 113 114 115 116 117 ... 149 150 151 152 153 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	3 feb 2025 12:41
Koers	0,840
Verschil	-0,026 (-3,00%)
Hoog	0,856
Laag	0,835
Volume	2.398.713
Volume gemiddeld	5.546.696
Volume gisteren	1.352.024

Pharming nieuws

21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming
31 dec	Morgan Stanley groter in Pharming
23 dec	CEO: Pharming koopt met KL1333 van Ab...
19 dec	RBC verhoogt koersdoel Pharming fors
16 dec	Afwachtend begin van Super Central Ba...
15 dec	CEO De Vries: Pharming dicht bij over...

Meer ››